Insulet Omnipod 5
The latest installment of Insulet’s (NSDQ:PODD) wearable, automated insulin delivery patch system, Omnipod 5, remains on track for FDA clearance and a subsequent launch later this year, President & CEO Shacey Petrovic said while announcing the company’s third-quarter earnings results.
Omnipod 5 will deliver a number of firsts to the market, building upon the Omnipod DASH, which was cleared in 2019. It will include pairing to Dexcom’s G6 CGM, making Omnipod 5 the first tubeless, wearable, automated insulin delivery system, Petrovic said in an interview earlier this year.
Patients will be able to use a dedicated handheld controller or control the system with a secure app on their smartphone, marking another first.
“We’ve seen in previous generations of other systems where complexity can really prevent people from getting good outcomes and having a good experience,” Petrovic said. “We worked very hard to take as much of the complexity out of the system and make it as easy for people to use as possible.”